ES8706965A1 - Un metodo de formacion de un conjugado de proteina y quelato metalico - Google Patents

Un metodo de formacion de un conjugado de proteina y quelato metalico

Info

Publication number
ES8706965A1
ES8706965A1 ES554387A ES554387A ES8706965A1 ES 8706965 A1 ES8706965 A1 ES 8706965A1 ES 554387 A ES554387 A ES 554387A ES 554387 A ES554387 A ES 554387A ES 8706965 A1 ES8706965 A1 ES 8706965A1
Authority
ES
Spain
Prior art keywords
protein
chelate
metal
metallic
context
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES554387A
Other languages
English (en)
Other versions
ES554387A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of ES8706965A1 publication Critical patent/ES8706965A1/es
Publication of ES554387A0 publication Critical patent/ES554387A0/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

METODO PARA FORMAR UN CONJUGADO DE PROTEINA Y QUELATO METALICO. COMPRENDE: A) PONER EN CONTACTO UN METAL, EN AUSENCIA DE PROTEINA CON UN QUELATO BIFUNCIONAL; Y B) MEZCLAR AL QUELATO METALICO CON UNA PROTEINA, EN UNA SOLUCION ACUOSA A UN PH ENTRE 6 Y 11, PARA FORMAR UN CONJUGADO ESTABLE DE PROTEINA Y QUELATO METALICO. EL METAL ES RADIONUCLIDO O FLUORESCENTE Y SE ELIGE ENTRE GADOLINIO O TRIENO; LA PROTEINA SE ELIGE ENTRE UNA PROTEINA DE LA SANGRE Y UN ANTICUERPO MONOCLONAL; Y EL QUELATO BIFUNCIONAL CONTIENE UN GRUPO FUNCIONAL UNIDO A UN ATOMO DE CARBONO DEL ESQUELETO DE QUELATO Y ES ESTABLE EN SOLUCION ACUOSA DILUIDA Y ES UN GRUPO ESTER DE N-HIDROXISUCCINIMIDA. SE UTILIZA PARA FORMAR UTILES EN LA TERAPIA Y DIAGNOSTICO DE LOS TUMORES.
ES554387A 1985-04-26 1986-04-25 Un metodo de formacion de un conjugado de proteina y quelato metalico Expired ES8706965A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/727,919 US4824986A (en) 1985-04-26 1985-04-26 Metal chelate protein conjugate

Publications (2)

Publication Number Publication Date
ES8706965A1 true ES8706965A1 (es) 1987-07-01
ES554387A0 ES554387A0 (es) 1987-07-01

Family

ID=24924643

Family Applications (1)

Application Number Title Priority Date Filing Date
ES554387A Expired ES8706965A1 (es) 1985-04-26 1986-04-25 Un metodo de formacion de un conjugado de proteina y quelato metalico

Country Status (10)

Country Link
US (1) US4824986A (es)
EP (3) EP0355860A1 (es)
JP (1) JPS62502618A (es)
KR (1) KR870700639A (es)
CN (1) CN86103488A (es)
AU (2) AU596590B2 (es)
BR (1) BR8606644A (es)
DK (1) DK627286A (es)
ES (1) ES8706965A1 (es)
WO (1) WO1986006384A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5227474A (en) * 1987-02-13 1993-07-13 Abbott Laboratories Bifunctional chelating agents
DE3710730A1 (de) * 1987-03-31 1988-10-20 Schering Ag Substituierte komplexbildner, komplexe und komplexsalze, verfahren zu deren herstellung und diese enthaltende pharmazeutische mittel
DE3728525A1 (de) * 1987-08-24 1989-03-16 Schering Ag Mehrkernige substituierte komplexbildner, komplexe und komplexsalze, verfahren zu deren herstellung und diese enthaltende pharmazeutische mittel
US5612016A (en) * 1988-04-01 1997-03-18 Immunomedics, Inc. Conjugates of antibodies and bifunctional ligands
US5059541A (en) * 1988-04-29 1991-10-22 Neorx Corporation Minimal derivatization of proteins
IE980696A1 (en) 1988-10-31 2000-12-13 Dow Chemical Co Chelants processing ortho ligating functionality and complexes thereof
BR8907282A (pt) * 1988-12-23 1991-03-12 Dow Chemical Co Processo para preparar complexos de metal funcionalizados com isotiocianato
US5364613A (en) * 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
US6039931A (en) * 1989-06-30 2000-03-21 Schering Aktiengesellschaft Derivatized DTPA complexes, pharmaceutical agents containing these compounds, their use, and processes for their production
US5695739A (en) * 1989-06-30 1997-12-09 Schering Aktiengesellschaft Derivatized DTPA complexes, pharmaceutical agents containing these compounds, their use, and processes for their production
DE3922005A1 (de) * 1989-06-30 1991-01-10 Schering Ag Derivatisierte dtpa-komplexe, diese verbindungen enthaltende pharmazeutische mittel, ihre verwendung und verfahren zu deren herstellung
US5112946A (en) * 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
US5686410A (en) * 1989-07-20 1997-11-11 Novartis Ag Polypeptide derivatives
US5124471A (en) * 1990-03-26 1992-06-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Bifunctional dtpa-type ligand
DE4136489A1 (de) * 1991-11-06 1993-05-13 Bayer Ag Neue diethylentriamin-derivate und deren verwendung zu diagnostischen und therapeutischen zwecken
US5403862A (en) * 1992-01-17 1995-04-04 University Of Utah Research Foundation Method for oral decorporation of metals
US5494935A (en) * 1992-01-17 1996-02-27 University Of Utah Research Foundation Methods for oral decorporation of metals
US5292729A (en) * 1992-08-14 1994-03-08 Albion International, Inc. II-bond aromatic vitamin chelates
US5672335A (en) * 1994-11-30 1997-09-30 Schering Aktiengesellschaft Use of metal complexes as liver and gallbladder X-ray diagnostic agents
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US6107090A (en) 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
IT1291623B1 (it) * 1997-04-18 1999-01-11 Bracco Spa Procedimento per la coniugazione di chelanti con molecole contenenti gruppi amminici
US6740756B1 (en) * 1998-07-07 2004-05-25 Smithkline Beecham Corporation Fluorescent lanthanide chelates
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US20020102208A1 (en) * 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
JP4619651B2 (ja) 2001-06-01 2011-01-26 コーネル・リサーチ・ファンデーション・インコーポレイテッド 前立腺特異的膜抗原に対する修飾抗体およびその使用
US7514078B2 (en) 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
IL159422A0 (en) 2001-09-20 2004-06-01 Cornell Res Foundation Inc Methods and compositions for treating or preventing skin disorders using binding agents specific for prostate-specific membrane antigen
ATE408712T1 (de) 2003-01-10 2008-10-15 Millennium Pharm Inc Verfahren zur bestimmung des wiederauftretens von prostata krebs
JP4912153B2 (ja) 2003-12-01 2012-04-11 イミューノメディクス、インコーポレイテッド タンパク質とキレート剤とのコンジュゲートを調製するための改良された方法
CA3121103C (en) * 2018-11-28 2023-10-10 Cube Biotech Gmbh Solid-phase chelator material, method for producing thereof and use thereof for the purification of proteins

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4622420A (en) * 1980-03-18 1986-11-11 The Regents Of The University Of California Chelating agents and method
CA1178951A (en) * 1980-03-18 1984-12-04 Claude F. Meares Chelating agents and method
NO169947C (no) * 1981-10-27 1992-08-26 Hybritech Inc Fremgangsmaate for fremstilling av et monoklonalt antistoff til et tumorassosiert antigen
US4472509A (en) * 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4454106A (en) * 1982-06-07 1984-06-12 Gansow Otto A Use of metal chelate conjugated monoclonal antibodies
GB2122641B (en) * 1982-06-07 1986-08-06 Otto A Gansow Metal chelate conjugated monoclonal antibodies where in the metal is an emitter
US4652519A (en) * 1983-02-03 1987-03-24 Yeda Research And Development Company Limited Bifunctional chelating agents and process for their production

Also Published As

Publication number Publication date
AU5780086A (en) 1986-11-18
EP0315220A1 (en) 1989-05-10
CN86103488A (zh) 1987-05-27
KR870700639A (ko) 1987-12-30
AU596590B2 (en) 1990-05-10
EP0220279A1 (en) 1987-05-06
AU4932490A (en) 1990-06-07
DK627286D0 (da) 1986-12-23
DK627286A (da) 1987-02-26
US4824986A (en) 1989-04-25
EP0355860A1 (en) 1990-02-28
BR8606644A (pt) 1987-08-04
JPS62502618A (ja) 1987-10-08
WO1986006384A1 (en) 1986-11-06
ES554387A0 (es) 1987-07-01

Similar Documents

Publication Publication Date Title
EP0270340A3 (en) Detection of necrotic malignant tissue ansd associated therapy
IL84866A0 (en) Method for detecting tumors
ES2053440T3 (es) Anticuerpos monoclonales anti-cancer de mama humano, correspondientes hibridomas, la produccion y utilizacion de los mismos.
FI955319A0 (fi) 2-pyridyylimetyleenipolyatsamakrosyklofosfonihappoja, niiden komplekseja ja johdannaisia käytettäväksi vasta-aineina
ATE67679T1 (de) Einen makrozyklischen koordinat und einen antikoerper enthaltende konjugatverbindung.
EP0248887A4 (en) CELL-FREE T-CELL ANTIGUE RECEPTOR AND CLINICAL USE.
ATE54417T1 (de) Radioaktiv markierte antikoerperstuecke.
PT1157041E (pt) Anticorpos para terapia e diagnostico de cancro
ES2102007T3 (es) Proteinas de fusion de fragmentos de anticuerpo monomeras y dimeras.
KR840003815A (ko) 효소와 항체의 공유결합에 의해 결합된 접합체의 제조방법
BG101024A (bg) Моноклонално антитяло срещу сd44v6
KR910005862A (ko) 신규 친수성 유도체, 진단 또는 치료시 그의 응용 그를 함유하는 진단 또는 치료용 키트 및 면역 시약
DE69315213D1 (de) Photoaktivierung von proteinen zu konjugationszwecken
IT8004812A0 (it) Procedimento per la riduzione di emissione di nox.
DE59010918D1 (de) Aminoalkylmaleimide und davon abgeleitete hapten- und antigenderivate sowie konjugate mit peptiden oder proteinen
ATE69891T1 (de) Monoklonalantikoerperabfassung fuer diagnostischen gebrauch.
IT1207589B (it) Composizione di anticorpi monoclonali umani cross-protettivi.
ES8403623A1 (es) Procedimiento para la determinacion de bilirrubina directa y total en liquidos corporales.
IT8221544A0 (it) Formazione terrestre sottostante ad metodo per la determinazione del un corpo d'acqua mediante potenziale idrocarburico di una l'analisi di affioramenti contenenti basse concentrazioni dimetano.
ES8604694A1 (es) Mejoras introducidas en un metodo de inmunoensayo para determinar una yodotironina en un fluido biologico
FI891718A0 (fi) Foerfarande foer att befria cellblandningar och vaevnader av icke-oenskade populationer.
DE3478958D1 (en) Protein conjugates of penicilloic acid, their preparation and use
IT1307864B1 (it) Metodo diagnostico per il riconoscimento di neoplasie umane attraversola determinazione dell'isoforma ctn-c della tn-c, frammenti di
FI854627A7 (fi) Menetelmä ja reagenssi plasmassa, seerumissa tai kokoveressä olevan vapaan tyroksiinin kvantitatiiviseksi määrittämiseksi.
EP0057236A4 (en) METHOD FOR DETERMINING A SIDE CHAIN OF GLUCOSE ASSOCIATED WITH A TUMOR, METHOD FOR DIAGNOSING TUMORS, AND "KIT" FOR DIAGNOSING TUMORS.